MS and Demyelinating Disorders

Findings from the OCARINA I study presented at the MSMilan 2023 meeting showed that a 920 mg subcutaneous dose of ocrelizumab was well-tolerated in patients with relapsing or primary progressive multiple sclerosis, with similar exposure to the FDA-approved intravenous dose.

A recent analysis presented at MSMilan 2023 showed significant cognitive and biomarker improvements among patients with progressive multiple sclerosis receiving repeated intrathecal injections of autologous mesenchymal stem cells.

The director of the Multiple Sclerosis Program at UCLA discussed the need to consider HRT among women with MS going through menopause, and how HRT can improve its negative effects. [WATCH TIME: 4 minutes]

A new analysis of the SAkuraMoon study showed that annual relapse rate remained consistently low in satralizumab-treated patients, with high proportions of patients remaining free from relapse, severe relapse, and worsening in disability.

Despite not showing significant associations, those with B cell suppression had longer time to relapse, new MRI activity, and progression independent of relapse activity than those without.

The founder and chief executive officer of Joi Life Wellness Group Multiple Sclerosis Center provided insight on the barriers with expanding precision medicine and the need for additional biomarkers of clinical progression. [WATCH TIME: 3 minutes]

The administration of a subcutaneous 920-mg dose resulted in near-complete suppression of radiological and clinical disease activity as measured up to week 24, similar to the intravenous therapy.

Using a minimally invasive neuromodulation device, patients showed decreases in Overactive Bladder questionnaire symptoms and increases in OAB-q quality of life scores.

A recent analysis of the PREVENT and CHAMPION-NMOSD found no significant differences in safety outcomes for patients with AQP4+ NMOSD who were treated with rituximab prior to starting C5 complement inhibitors in specific timeframes.

Following the switch from natalizumab, patients with multiple sclerosis on anti-CD20 therapies like rituximab demonstrated significant reductions in annualized relapse rate.

Catch up on any of the neurology news headlines you may have missed over the course of September 2023, compiled all into one place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is sleep disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 6, 2023.

Researchers proposed a harmonized definition of progression independent of relapse activity that may improve the comparability of results in current and future study cohorts, according to a newly published systematic review.

After being diagnosed with acute flaccid myelitis more than 10 years ago, patient advocate Sarah Todd Hammer spoke on the ways in which disability should be viewed and discussed.

The associate professor of neurology at Icahn School of Medicine at Mount Sinai talked about the promising new treatments for multiple sclerosis, the significance of the spinal cord in the disease, and the use of artificial intelligence in neuroimaging. [WATCH TIME: 3 minutes]

The adjusted odds ratios observed for any vaccine and MS flare-ups requiring hospitalization were similar regardless of sex, with the highest odds observed for the pneumococcal vaccine.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is epilepsy and seizure disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 29, 2023.

Erin Longbrake, MD, PhD, associate professor of neurology at Yale School of Medicine, discussed the importance of understanding rare autoimmune disorders to effectively design clinical trials and treatment strategies, especially for heterogeneous conditions like NMOSD and MOGAD.

The professor of neurology at Stony Brook University Medical Center discussed the progress observed in the field of multiple sclerosis and the lack of effective treatments for progressive forms of the disease. [WATCH TIME: 3 minutes]

The associate professor of neurology at Yale School of Medicine discussed the differentiation of neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein -associated disease from multiple sclerosis at IFN 2023. [WATCH TIME: 5 minutes]

Review the latest peer-reviewed articles dedicated to the multidisciplinary management of multiple sclerosis published in the International Journal of MS Care.